Boron-containing compounds as labels,drugs,and theranostic agents for diabetes and its complications  

作　　者：Marvin A Soriano-Ursúa R Ivan Cordova-Chávez Eunice D Farfan-García George Kabalka 

机构地区：[1]Department of Physiology,Escuela Superior de Medicina,Instituto Politécnico Nacional,Ciudad de México 11340,Mexico [2]Department of Physiology,Instituto Politécnico Nacional,Mexico City 11340,Mexico [3]Department of Biochemistry,Instituto Politécnico Nacional,Mexico City 11340,Mexico [4]Department of Chemistry,The University of Tennessee,Knoxville,TN 37996,United States

出　　处：《World Journal of Diabetes》2024年第6期1060-1069,共10页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by the Secretaría de Investigación y Posgrado,No.M2143,No.M2303,No.20232777,and No.4288/2023.

摘　　要：Diabetes is a disease with a high global burden.Current strategies have failed to limit the advancement and impact of the disease.Successful early diagnosis and treatment will require the development of new agents.In this sense,boroncontaining compounds have been reported as agents with the ability to reduce glycemia and lipidemia.They have also been used for labeling and measuring carbohydrates and other molecules linked to the initial stages of diabetes and its progression.In addition,certain boron compounds bind to molecules related to diabetes development and their biological activity in the regulation of elevated glycemia.Finally,it should be noted that some boron compounds appear to exert beneficial effects on diabetes complications such as accelerating wound healing while ameliorating pain in diabetic patients.

关 键 词：BORON Carbohydrates Metabolism DIABETES Boronodipyrromethene 

分 类 号：R587.2[医药卫生—内分泌] R57[医药卫生—内科学]